Loading quotes...

Forecast

The analysts' average price target is €9.37 (+163.94%). The median is €9.37 (+163.94%).

Buy	13
Hold	3
Sell	0

News Go to news feed

Aclaris outlines pipeline, financing and upcoming study data

Aclaris presented at the Cantor Fitzgerald Healthcare Conference a development plan focused on bispecific antibodies, ITK programs and lichen planus. The company expects multiple Phase‑1b readouts within nine months, including ATI‑052 in asthma and atopic dermatitis, and plans to start a lichen planus study; with positive interim data, regulatory discussions could be possible in 1H 2027. Management says cash on hand is sufficient through the end of 2028 to fund asthma, lichen planus, EoE proof‑of‑concept work and both ITK programs, but the Phase‑2b study in atopic dermatitis is only partially funded, so additional capital is likely required. » More on de.investing.com
Aclaris Therapeutics: Stifel raises price target to $4 as ATI-052 and ATI-2138 make clinical progress

Stifel reiterated a Hold on Aclaris Therapeutics and raised its price target to $4, citing optimism about the company’s multi-targeting immunology approaches. Aclaris reported positive Phase 1a SAD/MAD results for bispecific antibody ATI-052 and is awaiting top-line Phase 1b proof-of-concept data, while advancing ATI-2138 for lichen planus. Q1 revenue rose to $2.0 million from $1.5 million driven by higher royalties, but the company posted a net loss of $19.8 million versus $15.1 million a year earlier. » More on finance.yahoo.com
Aclaris reports positive phase‑1a data for bispecific antibody ATI‑052 and launches plans for ATI‑2138 in lichen planus

Aclaris disclosed full phase‑1a results for ATI‑052: the bispecific antibody showed an estimated half‑life of about 45 days, dose‑proportional pharmacokinetics, sustained inhibition of relevant biomarkers and good tolerability with no safety signals. Recruitment for phase‑1b studies in asthma and atopic dermatitis is ongoing, with results expected in H2 2026 and a phase‑2b program for asthma planned for Q4 2026. In addition, Aclaris plans a phase‑2b basket study with the dual inhibitor ATI‑2138 in erosive mucosal and cutaneous lichen planus in H2 2026; there are currently no FDA‑approved therapies for lichen planus. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2022, Aclaris Therapeutics has already paid €23.47 in dividends. The last payout was in June 2022.

Financials

In the last quarter, Aclaris Therapeutics had revenue of €1.43m and net profit of -€18.84m

(EUR)	June 2026	YoY
Revenue	1.43m	5.33%
Gross profit	1.22m	2,077.80%
Net profit	-18.84m	43.95%
EBITDA	-18.75m	31.59%

Fundamentals

Metric	Value
Market capitalization	€533.96m
Number of shares	147.2m
52-week high/low	€5.89 - €1.87
Dividends	No
Beta	0.80
P/E ratio	-7.01
PEG ratio	-0.15
P/B ratio	4.66
P/S ratio	72.80

Company profile

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.